Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 20, 2012 Rajesh Parishwad	India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
Reason February 2002 Mike Godwin	Prescription Panic How the anthrax scare challenged drug patents...
National Real Estate Investor July 1, 2006 Matt Hudgins	Eminent Domain: A Year After Kelo Legislative action in response to the Kelo decision is winding down, eminent domain will remain a hot issue into 2007 and beyond. That's because new eminent domain laws enacted by legislatures around the nation will be tested in the courts.
The Motley Fool December 14, 2006 Stephen Albainy-Jenei	Merck Gets Punk'd by Thailand Thailand issues a compulsory license to manufacture a generic version of Merck's patented AIDS drug. This is an act of humanitarian aid, but it is also an avenue for price and profit erosion worldwide.
The Motley Fool February 22, 2007 Dan Caplinger	Taking Away Your Property Investors may rightly wonder how recent limitations on eminent domain will affect private companies.
The Motley Fool March 14, 2008 Stephen Albainy-Jenei	The War on (the Cost of) Drugs Pharmaceutical companies could be hurt by countries disregarding drug patents.
Chemistry World January 21, 2013 Andy Extance	India pushes for emergency drug licenses The Indian government is preparing to grant compulsory licenses allowing three patented cancer drugs to be produced in the country and sold at reduced rates without permission from the patent owners.
Reason November 2005 Tim Cavanaugh	Property Seizures and the New London Tea Party Homeowners' attorney Scott Bullock talks about the Supreme Court's Kelo v. New London decision and America's brewing revolution against eminent domain abuse.
National Real Estate Investor May 1, 2005 Matt Hudgins	When is Eminent Domain Eminently Unfair? Developers counting on city governments to use eminent domain to clear urban renewal sites are watching to see if the U.S. Supreme Court favors property owners in a high-profile eminent domain dispute.
Commercial Investment Real Estate Sep/Oct 2005 Lewis G. Feldman	Domain Decision In its Kelo v. City of New London decision, the Supreme Court finds economic development qualifies as public use. Whether the decision will make it easier for private developers involved in municipal public/private partnerships remains to be seen.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
Linux Journal May 1, 2002 Lawrence Rosen	The Role of Standards in Open Source And, on how new standards are often compatible with free and open-source licensing...
Reason January 2006 Jacob Sullum	Takings, Take 2 State courts, where the battle over eminent domain is now shifting, don't necessarily agree with the U.S. Supreme Court's 2005 ruling in Kelo v. New London.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
Chemistry World February 15, 2007 Victoria Gill	Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.
Reason April 2007 Radley Balko	Official Extortion The U.S. Supreme Court recently refused to hear the case of an entrepreneur in Port Chester, New York. It thus let stand one of the more egregious abuses of eminent domain authority since the court's infamous Kelo v. New London case.
National Real Estate Investor August 1, 2005 Parke Chapman	There for the Taking Less than one month after the Supreme Court affirmed that economic development is a legal basis for eminent domain, state legislators are pushing back.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
Reason Aug/Sep 2007 Ilya Somin	The Limits of Anti-Kelo Legislation Reformers are trying to outlaw eminent domain abuse. But will the laws they're passing be effective?
Pharmaceutical Executive August 1, 2005 Jill Wechsler	Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.
Entrepreneur January 2005 Joshua Kurlantzick	Eminent Danger Small businesses can be decimated by eminent domain. Location is crucial to their success, and when they move, they can lose out.
Reason October 2007 Jacob Sullum	Kick 'Em While They're Down A new report from the Institute for Justice looked at 184 areas where the use of eminent domain was approved for private economic development projects. On average, the residents were poorer, less educated, less likely to own property, and more likely to be racial minorities.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Reason December 2007	Letters The Real Bill Richardson... Robert Heinlein at 100... The Limits of Anti-Kelo Legislation... etc.
Commercial Investment Real Estate Jan/Feb 2005 Robert McMurry	Domain Disputes Land-use issues gain new attention in the court system.
Bio-IT World June 17, 2004 Cathryn Campbell	Patent Plaintiff Perils Suing for patent infringement may seem rewarding, but you could lose even more.
Chemistry World October 29, 2007 Arthur Rogers	Deal to Allow Poor Nations Better Access to Cheap Drugs MEPs belatedly approved EU ratification of a 2005 World Trade Organization protocol on compulsory licensing -- potentially paving the way for developing countries to order generic drugs from manufacturers abroad without infringing patent rights.
Reason March 2008 Nick Gillespie	Litigating for Liberty The Institute for Justice's Chip Mellor on campaign-finance reform, eminent-domain abuse, and licensing laws gone wild.
InternetNews May 31, 2005 Jim Wagner	OSI Group to Slow License Influx? Officials will begin addressing the open source license rush in June, but it wants the community involved.
Reason November 2005 Matt Welch	"Like Undermining Motherhood and Apple Pie" Why are California Democrats in local government embracing eminent domain abuse?
Reason February 2003 Sam Staley	Wrecking Property Rights How cities use eminent domain to seize property for private developers.
Commercial Investment Real Estate Nov/Dec 2006 Jon M. Anderson	Interpreting the Rules A Rhode Island court decision illustrates conflicting opinions on eminent domain.
Salon.com October 18, 2001 Anthony York	Is it time to bust the Cipro patent? Activist Jamie Love accuses the Bush administration of putting corporate profits above public safety...
Bio-IT World November 19, 2004 Lentini & Bent	Intellectual Property: Patents and Genomic Medicine Patents, so critical to encouraging investment in developing new technologies, threaten to become a legal and economic minefield that could prevent effective commercial exploitation of genomics.
Commercial Investment Real Estate Jan/Feb 2009 Andrew Prince Brigham	What's it Worth? Eminent domain challenges the property valuation process.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
Chemistry World August 6, 2007 Victoria Gill	Novartis Loses Indian Patent Law Case Swiss drug firm Novartis has lost its legal case against the Indian government, who it had accused of 'unconstitutional' patent law practices. The ruling sets an important precedent that will cheer the flourishing generics market in the country.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
Reason October 2005 Matt Welch	Why The New York Times "Hearts" Eminent Domain Elite newspapers and liberal activists embrace the Supreme Court Kelo v. City of New London decision at their long-term peril.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Pharmaceutical Executive April 1, 2012 William Looney	IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Bio-IT World September 9, 2002 Jim Gatto	Open Source: Not Yet a Closed Case Biotech companies should weigh both the benefits and risks before choosing open source software.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
Reason May 2005 Daniel McGraw	Demolishing Sports Welfare Two court cases could mean the end of publicly funded stadiums.
National Real Estate Investor February 1, 2006 Fleming & Chapman	Eminent Outrage After 30 years of sprawl and growing opposition to development, the Kelo v. New London Supreme Court decision set off a firestorm of protests that threatens all new projects.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.